FEATURED BLOGS
Jul 20, 2018
Dr. Jaime G. de la Garza-Salazar shares the story of how one of the first international Best of ASCO Meetings came to be.
Jul 18, 2018
The ASCO Annual Meeting is over, and now we return to our routines—in our clinics and hospitals, offices and operating rooms, labs and libraries, classrooms and conference rooms. I hope these stories...
Jul 18, 2018
"The challenges that affect the growth of a physician are not limited to a curriculum but are also about emotional growth." Dr. Samah Nassereddine describes the growing pains of her first year of...
Jul 16, 2018
Broadening eligibility critera for cancer clinical trials will give more patients the opportunity to contribute to scientific research.
Jul 11, 2018
Every patient with cancer deserves equal access to the highest quality care and the opportunity to participate in research.
Jul 11, 2018
ASCO CMO Dr. Richard L. Schilsky invites all cancer researchers to come together for education and networking around cancer clinical trials.
Jun 22, 2018
At the most recent meeting, ASCO's delegation to the AMA House of Delegates were involved in resolutions related to Pharmacy Benefit Managers, opioids, billing for survivorship care plans, alcohol as...

Advertisement

Most Read

This was a patient who needed to do cancer her way, and making it about me was not going to work.
Monica M. Bertagnolli, MD, FACS, FASCO, has always been a trailblazer, both in her field and in the ranks of leadership. Her next role? 2018–2019 ASCO President.
Dr. Arjun Gupta reconsidered an order (and the evidence) for a neutropenic diet when it negatively affected his patient's quality of life.  
At the most recent meeting, ASCO's delegation to the AMA House of Delegates were involved in resolutions related to Pharmacy Benefit Managers, opioids, billing for survivorship care plans, alcohol as a modifiable risk for cancer, and more.
As a pragmatic investigator and physician who has witnessed remarkable progress in the treatments we can now offer individuals with cancer, I believe the FDA’s support of more rapid and nimble testing and approval of new therapies should be applauded. 

Tweets from ASCO

Tweets from Oncology Community